Clinical, Biochemical and Neurological Outcomes in Bipolar Patients with Lithium Intoxication at A Tertiary Care Hospital Sindh

Main Article Content

Kulsoom Lashari
Fatima Soomro
Muhammad Ilyas
Raz Muhammad Kakar
Sangeet
Shehroz Khan
Mahenoor Channa
Kartaar Saahil

Abstract

Background: Bipolar disorder (BD) affects a significant portion of the global population, with lithium being a cornerstone in its treatment. However, the therapeutic index of lithium is narrow, and its effectiveness can be overshadowed by the risk of toxicity, especially at higher serum levels. Understanding the impact of varying lithium concentrations on clinical, biochemical, and neurological outcomes is crucial in the management of BD.


Objective: To assess the clinical, biochemical, and neurological changes associated with different levels of lithium toxicity in patients with bipolar disorder and to determine the safe and effective range of lithium serum levels.


Methods: A prospective cross-sectional study was conducted at Jinnah Post Graduate Medical Center, Karachi, involving 100 bipolar disorder patients on lithium therapy, categorized into three groups based on their serum lithium levels: Category I (<1.2 mmol/L), Category II (1.2 – 2.5 mmol/L), and Category III (>2.5 mmol/L). Clinical assessments, laboratory investigations (including renal and thyroid function tests), and neurological evaluations were conducted. Data were analyzed using SPSS version 25, with the t-test and Chi-square test employed for quantitative and qualitative comparisons, respectively.


Results: Patients with serum lithium levels above 2.5 mmol/L (Category III) demonstrated significantly higher rates of clinical toxicity, renal dysfunction, and neurological complications compared to lower lithium level groups. Renal function parameters (serum creatinine and urea) and thyroid function (TSH levels) were notably altered in Category III. The incidence of neuropsychiatric symptoms was also significantly higher in this group, with severe neurotoxic effects observed in 27% of these patients.


Conclusion: The study highlights the critical importance of maintaining serum lithium levels within a therapeutic range to avoid severe adverse effects. Lithium levels above 2.5 mmol/L significantly increase the risk of renal dysfunction, thyroid abnormalities, and neurotoxicity. Regular monitoring and individualized treatment adjustments are essential for optimizing patient safety and treatment efficacy.

Article Details

How to Cite
Lashari, K., Soomro, F., Ilyas, M., Kakar, R. M., Sangeet, Khan, S., Channa, M., & Saahil, K. (2024). Clinical, Biochemical and Neurological Outcomes in Bipolar Patients with Lithium Intoxication at A Tertiary Care Hospital Sindh. Journal of Health and Rehabilitation Research, 4(1), 133–139. https://doi.org/10.61919/jhrr.v4i1.302
Section
Articles
Author Biographies

Kulsoom Lashari, Jinnah Post Graduate Medical Center Karachi

Fcps Consultant Department of Psychiatry

Fatima Soomro, Jinnah Postgraduate Medical Centre (JPMC)-Karachi

Post Graduate Resident

Muhammad Ilyas, Balochistan Institute Of Psychiatry And Behavioral Sciences Quetta

Assistant Professor Psychiatry

Raz Muhammad Kakar, BMC Hospital- Quetta

Professor of Neurosurgery

Sangeet, Jinnah Postgraduate Medical Centre (JPMC)-Karachi

Fcps Post Graduate Resident

Mahenoor Channa, Jinnah Postgraduate Medical Centre (JPMC)-Karachi

Post Graduate Psychiatry Resident

References

Pettigrew JD. Bipolar Disorder. In: Ramachandran VS, editor. Encyclopedia of Human Behavior (Second Edition). Academic Press; 2012. p. 348-52.

Diagnosis and management of bipolar disorders. BMJ. 2023;381:e073591.

Iqbal SM, Rahman R-U, Saad M, Farid J, Zafar S. Prevalence of vulnerability for bipolar spectrum disorder among students of Pakistan. Int J Appl Behav Sci. 2014;1(2):3-8.

Fountoulakis KN, Tohen M, Zarate CA Jr. Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol. 2022;54:100-15.

Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383(1):58-66.

Chatterjee D, Beaulieu JM. Inhibition of glycogen synthase kinase 3 by lithium, a mechanism in search of specificity. Front Mol Neurosci. 2022;15:1028963.

Ferensztajn-Rochowiak E, Rybakowski JK. Long-Term Lithium Therapy: Side Effects and Interactions. Pharmaceuticals (Basel). 2023;16(1):74.

Won E, Kim Y-K. An oldie but goodie: lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int J Mol Sci. 2017;18(12):2679.

El-sayed Hamdey El-sayed Gawesh et al. Clinical, laboratory and neurological assessment of lithium toxicity in patients with bipolar disorders. J Popul Ther Clin Pharmacol. 2023;30(4):379-91.

Janicak PG. Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects. UpToDate; 2021.

Netto I, Phutane VH. Reversible lithium neurotoxicity: review of the literature. Prim Care Companion CNS Disord. 2012;14(1):PCC.11r01197.

Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28(1):38-49. 13. Mohandas E, Rajmohan V. Lithium use in special populations. Indian J Psychiatry. 2007;49(3):211-18.

Delva NJ, Hawken ER. Preventing lithium intoxication. Guide for physicians. Can Fam Physician. 2001;47:1595-600.

El-Mallakh RS. Treatment of acute lithium toxicity. Vet Hum Toxicol. 1984;26(1):31-35.

Lum G. Lithium self-intoxication treated with hemodialysis. Lab Med. 2007;38(11):667-68.

Bosi A, Clase CM, Ceriani L, Sjölander A, Fu EL, Runesson B, Chang Z, Landén M, Bellocco R, Elinder CG, Carrero JJ. Absolute and Relative Risks of Kidney Outcomes Associated With Lithium vs Valproate Use in Sweden. JAMA Netw Open. 2023;6(7):e2322056.

Bastiampillai T, Gupta A, Allison S, Chan SKW. NICE guidance: why not clozapine for treatment-refractory bipolar disorder? Lancet Psychiatry. 2016;3(6):502-3.

Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiatry. 2015;72(12):1182-91.

Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386(9992):461-68.

Kores B, Lader MH. Irreversible lithium neurotoxicity: an overview. Clin Neuropharmacol. 1997;20(4):283-99.

Donaldson IM, Cuningham J. Persisting neurologic sequelae of lithium carbonate therapy. Arch Neurol. 1983;40(12):747-51.

Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol. 1987;7(2):89-91.

Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry. 1989;146(2):278.

Muly EC, McDonald W, Steffens D, et al. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry. 1993;150(10):1565.

Czarnywojtek A, Zgorzalewicz-Stachowiak M, Czarnocka B, Sawicka-Gutaj N, Gut P, Krela-Kazmierczak I, Ruchala M. Effect of lithium carbonate on the function of the thyroid gland: mechanism of action and clinical implications. J Physiol Pharmacol. 2020;71(2):10.26402/jpp.2020.2.03.

Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):723-33.

Most read articles by the same author(s)